Cargando…

Plasma neuregulin 1 as a synaptic biomarker in Alzheimer’s disease: a discovery cohort study

BACKGROUND: Synaptic dysfunction is an early core feature of Alzheimer’s disease (AD), closely associated with cognitive symptoms. Neuregulin 1 (NRG1) is a growth and differentiation factor with a key role in the development and maintenance of synaptic transmission. Previous reports have shown that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vrillon, Agathe, Mouton-Liger, François, Martinet, Matthieu, Cognat, Emmanuel, Hourregue, Claire, Dumurgier, Julien, Bouaziz-Amar, Elodie, Brinkmalm, Ann, Blennow, Kaj, Zetterberg, Henrik, Hugon, Jacques, Paquet, Claire
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125890/ https://www.ncbi.nlm.nih.gov/pubmed/35606871 http://dx.doi.org/10.1186/s13195-022-01014-7

Ejemplares similares

Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice
por: Lilamand, Matthieu, et al.
Publicado: (2022)

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
por: Mouton-Liger, François, et al.
Publicado: (2020)

Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry
por: Camporesi, Elena, et al.
Publicado: (2022)

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
por: Öhrfelt, Annika, et al.
Publicado: (2016)

Full-length and C-terminal neurogranin in Alzheimer’s disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays
por: Öhrfelt, Annika, et al.
Publicado: (2020)

Blood-Based Kinase Assessments in Alzheimer’s Disease
por: Hugon, Jacques, et al.
Publicado: (2018)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
por: Boumenir, Adla, et al.
Publicado: (2019)

Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau
por: Lafirdeen, Aysha S. Mohamed, et al.
Publicado: (2019)

PKR involvement in Alzheimer’s disease
por: Hugon, Jacques, et al.
Publicado: (2017)

Are ketogenic diets promising for Alzheimer’s disease? A translational review
por: Lilamand, Matthieu, et al.
Publicado: (2020)

A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging
por: Dumurgier, Julien, et al.
Publicado: (2022)

Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer’s Disease
por: Dumurgier, Julien, et al.
Publicado: (2013)

Fluid Biomarkers for Synaptic Dysfunction and Loss
por: Camporesi, Elena, et al.
Publicado: (2020)

Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study
por: Saddiki, Hana, et al.
Publicado: (2020)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

Using virtual reality in lumbar puncture training improves students learning experience
por: Vrillon, Agathe, et al.
Publicado: (2022)

Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study
por: Paquet, Claire, et al.
Publicado: (2016)

N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
por: Snellman, Anniina, et al.
Publicado: (2022)

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France
por: Cognat, Emmanuel, et al.
Publicado: (2019)

Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
por: Benedet, Andréa L., et al.
Publicado: (2021)

Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry
por: Sjödin, Simon, et al.
Publicado: (2016)

Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review
por: Davy, Vincent, et al.
Publicado: (2021)

Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer’s Disease
por: Paquet, Claire, et al.
Publicado: (2015)

Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease
por: Boza-Serrano, Antonio, et al.
Publicado: (2022)

PKR downregulation prevents neurodegeneration and β-amyloid production in a thiamine-deficient model
por: Mouton-Liger, F, et al.
Publicado: (2015)

Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders
por: Régy, Mélina, et al.
Publicado: (2023)

COVID-19 in adults with dementia: clinical features and risk factors of mortality—a clinical cohort study on 125 patients
por: Vrillon, Agathe, et al.
Publicado: (2021)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

Peripheral inflammation increases PKR activation, Tau phosphorylation and amyloid β production in wild-type mice
por: Mouton-Liger, François, et al.
Publicado: (2013)

Copper and zinc isotopic excursions in the human brain affected by Alzheimer's disease
por: Moynier, Frédéric, et al.
Publicado: (2020)

Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review
por: Lilamand, Matthieu, et al.
Publicado: (2022)

Expression and secretion of synaptic proteins during stem cell differentiation to cortical neurons
por: Nazir, Faisal Hayat, et al.
Publicado: (2018)

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2020)

Is the clinical phenotype impact the prognosis in dementia with Lewy bodies?
por: Aveneau, Clément, et al.
Publicado: (2023)

Neuroprotective role of PKR in a model of neurodegeneration due to mild impairment of oxidative metabolism
por: Mouton-Liger, François, et al.
Publicado: (2013)

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
por: Montoliu-Gaya, Laia, et al.
Publicado: (2023)

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
por: van den Berg, Emma, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jqkm2q90bff3dq3pqcvj2k73dl